{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T12:40:15Z","timestamp":1791895215485,"version":"4.3.4"},"reference-count":168,"publisher":"Scientific Scholar","issue":"02","license":[{"start":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T00:00:00Z","timestamp":1748217600000},"content-version":"vor","delay-in-days":55,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["South Asian J Cancer"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Colorectal cancer (CRC) is one of the most common malignancies across the world and is the fourth most common cancer among men in India as per the Global Cancer Observatory (GLOBOCAN) data 2020. Available data suggest that approximately 30% of patients present with advanced\/metastatic CRC (mCRC). This publication summarizes the latest evidence with cognizance of the unique challenges faced in India by medical oncologists treating mCRC.<\/jats:p>\n                  <jats:p>A panel of 38 medical oncologists held a meeting in February 2023 and reviewed the evidence available for the management of mCRC. The meeting concentrated on the recognition and management of mCRC with a focus on systemic therapeutic approaches. A literature review of these aspects of management leads to the formation of consensus statements with the level of evidence and grades of recommendation. Statements were evaluated by the modified Delphi method.<\/jats:p>\n                  <jats:p>The panel comprising 38 experts formulated 51 consensus statements with regard to the management of mCRC, including oligometastatic CRC, unresectable CRC, as well as various systemic therapeutic options. Resource-constrained scenarios, specifically with regard to the economic constraints and availability of drugs in India, were evaluated as part of the statements.<\/jats:p>\n                  <jats:p>Our consensus statements offer practical, yet evidence-based management guidelines for treating mCRC in the Indian context. Stratifying and recommending treatment options in a resource-constrained scenario is an important aspect of these statements.<\/jats:p>","DOI":"10.1055\/s-0045-1809380","type":"journal-article","created":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T19:35:46Z","timestamp":1748288146000},"page":"103-122","source":"Crossref","is-referenced-by-count":1,"title":["Consensus Statements for Clinical Practice in Advanced\/Metastatic Colorectal Cancers in India Using a Modified Delphi Method"],"prefix":"10.25259","volume":"14","author":[{"given":"Anant","family":"Ramaswamy","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tata Memorial Hospital (Homi Bhabha National Institute), Mumbai, Maharashtra India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujay","family":"Srinivas","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Bharath Hospital, Kottayam, Kerala, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1981-2693","authenticated-orcid":false,"given":"Viraj","family":"Lavingia","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Shalby Hospital, Ahmedabad, Gujarat, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mounika","family":"Boppana","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Haematoncology, Krishna Institute of Medical Sciences (KIMS) Hospital, Secunderabad, Hyderabad, Telangana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chakor","family":"Vora","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Sassoon General Hospital, Pune, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randeep","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Medical and Hemato-Oncology, Narayana Health, Gurugram, Haryana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Vamshi","family":"Krishna","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Haematology, Institute of Oncology AIG Hospitals, Hyderabad, Telangana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amish","family":"Vora","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, H.O.P.E. Oncology Clinic, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2932-2663","authenticated-orcid":false,"given":"Sujith Kumar","family":"Mullapally","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Apollo Proton Cancer Centre, Chennai, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6440-2186","authenticated-orcid":false,"given":"Prabhat","family":"Bhargava","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tata Memorial Hospital (Homi Bhabha National Institute), Mumbai, Maharashtra India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinayak","family":"Maka","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Ramaiah Medical College, Bengaluru, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gautam","family":"Goyal","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Hemato-Oncology, Max Super Specialty Hospital, Mohali, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1381-0320","authenticated-orcid":false,"given":"Vivek","family":"Agarwala","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Hemato-Oncology, Narayana Health, Kolkata, Bengal, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashay","family":"Karpe","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Sunrise Oncology Centre, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jimmy","family":"Mirani","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Wockhardt Hospital, Mumbai Central, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S Krupa","family":"Shankar","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, NSR CanKure Center, Coimbatore, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanmoy Kumar","family":"Mandal","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, AMRI Hospital, Dhakuria, Kolkata, West Bengal, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sourav Kumar","family":"Mishra","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology\/Hematology, All India Institute of Medical Sciences, Bhubaneswar, Odisha, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nisar Ahmad","family":"Syed","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Sheri Kashmir Institute of Medical Sciences SKIMS, Soura, Jammu and Kashmir, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atul","family":"Sharma","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Hemato-Oncology, Max Super Specialty Hospital, Saket, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shasanka Sekhar","family":"Das","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, HCG EKO Cancer Center, Kolkata, West Bengal, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2190-1927","authenticated-orcid":false,"given":"Soumya Surath","family":"Panda","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, IMS & SUM Hospital, Bhubaneswar, Odisha, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pradip Kumar","family":"Mondal","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Medica Super Specialty Hospital Mukundapur, Kolkata, West Bengal, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Hemato-Oncology, Jay Prabha Medanta Super Specialty Hospital, Patna, Bihar, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shekar","family":"Patil","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, HCG Hospital Bangalore, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh","family":"Pinninti","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Basavatarakam Indo-American Cancer Hospital & Research Institute, Hyderabad, Telangana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajoy Oommen","family":"John","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, CMC Vellore, Ranipet Campus, Vellore, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murtaza","family":"Bohra","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, National Cancer Institute, Nagpur, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rejiv","family":"Rajendranath","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Integrated Cancer Care Group, GEM Hospital, Institute of Gastroenterology and Laparoscopy, Chennai, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudeep","family":"Das","sequence":"additional","affiliation":[{"name":"Department of Medical and Hemato-Oncology, Medica Superspecialty Hospital, Mukundapur, Kolkata, West Bengal, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumit","family":"Goyal","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Rajiv Gandhi Cancer Institute and Research Centre, Rohini, Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh M.","family":"P.","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Amrita Institute of Medical Sciences, Kerala, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishnakumar","family":"Rathnam","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Meenakshi Mission Hospital, Chinthamani Madurai, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9516-8935","authenticated-orcid":false,"given":"Amol","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Command Hospital, Central Command, Lucknow, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boman","family":"Dhabhar","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Fortis Hospital Mulund, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditi","family":"Thanky","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Sterling Hospital, Rajkot, Gujarat, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vipul","family":"Doshi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Solapur Cancer Centre, Solapur, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6006-2631","authenticated-orcid":false,"given":"Akhil","family":"Kapoor","sequence":"additional","affiliation":[{"name":"Homi Bhabha Cancer Hospital and Mahamana Pandit Madan Mohan Malaviya Cancer Centre, Homi Bhabha National Institute, Varanasi"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nishitha","family":"Shetty","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Father Muller Medical College, Mangalore, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davinder","family":"Paul","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Fortis Hospital, Ludhiana, Punjab, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"George","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Manipal Hospital, Panaji, Goa, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akshay D.","family":"Baheti","sequence":"additional","affiliation":[{"name":"Department of Radiodiagnosis, Tata Memorial Hospital (Homi Bhabha National Institute), Mumbai, Maharashtra India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4511-7782","authenticated-orcid":false,"given":"Rahul","family":"Krishnatry","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Tata Memorial Hospital (Homi Bhabha National Institute), Mumbai, Maharashtra India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0067-4748","authenticated-orcid":false,"given":"Vikas","family":"Ostwal","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tata Memorial Hospital (Homi Bhabha National Institute), Mumbai, Maharashtra India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10894","published-online":{"date-parts":[[2025,5,26]]},"reference":[{"issue":"03","key":"ref1","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"H Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"02","key":"ref2","doi-asserted-by":"crossref","first-page":"91","DOI":"10.4103\/cmrp.cmrp_65_20","article-title":"Incidence of colorectal cancers in India: a review from population-based cancer registries","volume":"11","author":"S Asthana","year":"2021","journal-title":"Curr Med Res Pract"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"e16084","DOI":"10.1200\/JCO.2020.38.15_suppl.e16084","article-title":"Trends in colorectal cancer incidence in India","volume":"38","author":"V Mathew Thomas","year":"2020","journal-title":"J Clin Oncol"},{"issue":"04","key":"ref4","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1007\/s13193-017-0655-0","article-title":"Colorectal cancer in India: an audit from a tertiary center in a low prevalence area","volume":"8","author":"P S Patil","year":"2017","journal-title":"Indian J Surg Oncol"},{"issue":"01","key":"ref5","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1186\/s12885-021-08398-z","article-title":"Metastatic colo-rectal cancer: real life experience from an Indian tertiary care center","volume":"21","author":"V Sharma","year":"2021","journal-title":"BMC Cancer"},{"issue":"04","key":"ref6","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1055\/s-0041-1736203","article-title":"Treatment of metastatic colorectal cancers in resource-constrained low- and middle-income countries (LMICS) scenario-outcomes, practice patterns, and commentary on treatment costs","volume":"11","author":"A Ramaswamy","year":"2022","journal-title":"South Asian J Cancer"},{"issue":"01","key":"ref7","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","article-title":"Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"A Cervantes","year":"2023","journal-title":"Ann Oncol"},{"issue":"03","key":"ref8","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1200\/JCO.22.01690","article-title":"Treatment of metastatic colorectal cancer: ASCO guideline","volume":"41","author":"V K Morris","year":"2023","journal-title":"J Clin Oncol"},{"issue":"03","key":"ref9","doi-asserted-by":"crossref","first-page":"192","DOI":"10.4103\/0971-5851.142031","article-title":"Indian Council of Medical Research consensus document for the management of colorectal cancer","volume":"35","author":"B Sirohi","year":"2014","journal-title":"Indian J Med Paediatr Oncol"},{"issue":"10","key":"ref10","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1086\/656735","article-title":"Quality and strength of evidence of the Infectious Diseases Society of America clinical practice guidelines","volume":"51","author":"A R Khan","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"07","key":"ref11","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1056\/NEJM200502173520723","article-title":"Hepatic arterial infusion after liver resection","volume":"352","author":"N E Kemeny","year":"2005","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"887","DOI":"10.3109\/00365521.2011.574732","article-title":"Diagnostic accuracy of computed tomography for colon cancer staging: a systematic review","volume":"46","author":"A M Leufkens","year":"2011","journal-title":"Scand J Gastroenterol"},{"issue":"09","key":"ref13","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1002\/bjs.7096","article-title":"Accuracy of multidetector computed tomography in identifying poor prognostic factors in colonic cancer","volume":"97","author":"S Dighe","year":"2010","journal-title":"Br J Surg"},{"issue":"09","key":"ref14","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.crad.2010.01.024","article-title":"Diagnostic precision of CT in local staging of colon cancers: a meta-analysis","volume":"65","author":"S Dighe","year":"2010","journal-title":"Clin Radiol"},{"issue":"09","key":"ref15","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.3390\/cancers12092432","article-title":"Follow-up 18F-FDG PET\/CT versus contrast-enhanced CT after ablation of liver metastases of colorectal carcinoma - a cost-effectiveness analysis","volume":"12","author":"M L Schnitzer","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"S 01","key":"ref16","first-page":"28S","article-title":"Early detection of cancer recurrence: 18F-FDG PET\/CT can make a difference in diagnosis and patient care","volume":"48","author":"O Israel","year":"2007","journal-title":"J Nucl Med"},{"issue":"03","key":"ref17","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1148\/radiology.206.3.9494497","article-title":"Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET: correlation with histopathologic and CT findings","volume":"206","author":"H Abdel-Nabi","year":"1998","journal-title":"Radiology"},{"issue":"03","key":"ref18","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1245\/s10434-007-9626-y","article-title":"Positron emission tomography detection of distant metastatic or synchronous disease in patients with locally advanced rectal cancer receiving preoperative chemoradiation","volume":"15","author":"C SR Nahas","year":"2008","journal-title":"Ann Surg Oncol"},{"issue":"04","key":"ref19","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S0002-9610(99)00187-7","article-title":"Utility of 18F-FDG positron emission tomography scanning on selection of patients for resection of hepatic colorectal metastases","volume":"178","author":"Y Fong","year":"1999","journal-title":"Am J Surg"},{"issue":"11","key":"ref20","doi-asserted-by":"crossref","first-page":"4735","DOI":"10.1007\/s00330-018-5469-0","article-title":"Diagnostic accuracy of CE-CT, MRI and FDG PET\/CT for detecting colorectal cancer liver metastases in patients considered eligible for hepatic resection and\/or local ablation","volume":"28","author":"K Sivesgaard","year":"2018","journal-title":"Eur Radiol"},{"issue":"01","key":"ref21","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1007\/s00330-019-06369-4","article-title":"Consensus report from the 8th International Forum for Liver Magnetic Resonance Imaging","volume":"30","author":"C J Zech","year":"2020","journal-title":"Eur Radiol"},{"issue":"04","key":"ref22","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s11604-017-0622-2","article-title":"Comparison of gadoxetic acid-enhanced dynamic MR imaging and contrast-enhanced computed tomography for preoperative evaluation of colorectal liver metastases","volume":"35","author":"N Asato","year":"2017","journal-title":"Jpn J Radiol"},{"issue":"01","key":"ref23","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S1470-2045(23)00572-7","article-title":"MRI in addition to CT in patients scheduled for local therapy of colorectal liver metastases (CAMINO): an international, multicentre, prospective, diagnostic accuracy trial","volume":"25","author":"B G\u00f6rgec","year":"2024","journal-title":"Lancet Oncol"},{"issue":"20","key":"ref24","doi-asserted-by":"crossref","first-page":"4891","DOI":"10.3748\/wjg.v22.i20.4891","article-title":"Rectal cancer staging: Multidetector-row computed tomography diagnostic accuracy in assessment of mesorectal fascia invasion","volume":"22","author":"D Ippolito","year":"2016","journal-title":"World J Gastroenterol"},{"issue":"04","key":"ref25","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s13244-010-0037-4","article-title":"Magnetic resonance imaging (MRI) in rectal cancer: a comprehensive review","volume":"1","author":"M R Torkzad","year":"2010","journal-title":"Insights Imaging"},{"issue":"04","key":"ref26","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1080\/00365520701745842","article-title":"Transrectal ultrasonography and magnetic resonance imaging in the staging of rectal cancer. Effect of experience","volume":"43","author":"S R Rafaelsen","year":"2008","journal-title":"Scand J Gastroenterol"},{"issue":"04","key":"ref27","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1053\/j.sult.2005.04.005","article-title":"Imaging for predicting the risk factors\u2013the circumferential resection margin and nodal disease\u2013of local recurrence in rectal cancer: a meta-analysis","volume":"26","author":"M J Lahaye","year":"2005","journal-title":"Semin Ultrasound CT MR"},{"issue":"05","key":"ref28","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1046\/j.1463-1318.2003.00518.x","article-title":"MRI in rectal cancer: the T stage and circumferential resection margin","volume":"5","author":"R GH Beets-Tan","year":"2003","journal-title":"Colorectal Dis"},{"issue":"01","key":"ref29","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1200\/JCO.2012.45.3258","article-title":"Preoperative magnetic resonance imaging assessment of circumferential resection margin predicts disease-free survival and local recurrence: 5-year follow-up results of the MERCURY study","volume":"32","author":"F GM Taylor","year":"2014","journal-title":"J Clin Oncol"},{"issue":"01","key":"ref30","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1148\/radiology.211.1.r99ap35215","article-title":"Rectal carcinoma: thin-section MR imaging for staging in 28 patients","volume":"211","author":"G Brown","year":"1999","journal-title":"Radiology"},{"issue":"06","key":"ref31","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1097\/SLA.0b013e31815c29ff","article-title":"Long-term results of intersphincteric resection for low rectal cancer","volume":"246","author":"R Chamlou","year":"2007","journal-title":"Ann Surg"},{"issue":"17","key":"ref32","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1056\/NEJMoa0804385","article-title":"K-ras mutations and benefit from cetuximab in advanced colorectal cancer","volume":"359","author":"C S Karapetis","year":"2008","journal-title":"N Engl J Med"},{"issue":"10","key":"ref33","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1200\/JCO.2007.14.7116","article-title":"Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer","volume":"26","author":"R G Amado","year":"2008","journal-title":"J Clin Oncol"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"LBA387","DOI":"10.1200\/jco.2014.32.3_suppl.lba387","article-title":"Analysis of KRAS\/NRAS mutations in phase 3 study 20050181 of panitumumab (pmab) plus FOLFIRI versus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC)","volume":"32","author":"M Peeters","year":"2014","journal-title":"J Clin Oncol"},{"issue":"15","key":"ref35","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1200\/JCO.2010.33.5091","article-title":"Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status","volume":"29","author":"E Van Cutsem","year":"2011","journal-title":"J Clin Oncol"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1016\/S0140-6736(11)60613-2","article-title":"Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial","volume":"377","author":"T S Maughan","year":"2011","journal-title":"Lancet"},{"issue":"11","key":"ref37","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1056\/NEJMoa1305275","article-title":"Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer","volume":"369","author":"J Y Douillard","year":"2013","journal-title":"N Engl J Med"},{"issue":"24","key":"ref38","doi-asserted-by":"crossref","first-page":"5469","DOI":"10.1158\/1078-0432.CCR-15-0526","article-title":"Analysis of KRAS\/NRAS mutations in a Phase III Study of panitumumab with FOLFIRI compared with FOLFIRI alone as second-line treatment for metastatic colorectal cancer","volume":"21","author":"M Peeters","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"08","key":"ref39","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/S1470-2045(10)70130-3","article-title":"Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis","volume":"11","author":"W De Roock","year":"2010","journal-title":"Lancet Oncol"},{"issue":"06","key":"ref40","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1056\/NEJMoa0808268","article-title":"Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer","volume":"360","author":"J Tol","year":"2009","journal-title":"N Engl J Med"},{"issue":"01","key":"ref41","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1056\/NEJMc0904160","article-title":"BRAF mutation in metastatic colorectal cancer","volume":"361","author":"J Tol","year":"2009","journal-title":"N Engl J Med"},{"issue":"09","key":"ref42","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1002\/ijc.25555","article-title":"Optimizing targeted therapeutic development: analysis of a colorectal cancer patient population with the BRAF(V600E) mutation","volume":"128","author":"J Tie","year":"2011","journal-title":"Int J Cancer"},{"issue":"16","key":"ref43","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1200\/JCO.2014.59.7633","article-title":"Metastatic colorectal cancer: current state and future directions","volume":"33","author":"M G Fakih","year":"2015","journal-title":"J Clin Oncol"},{"issue":"35","key":"ref44","doi-asserted-by":"crossref","first-page":"5705","DOI":"10.1200\/JCO.2008.18.0786","article-title":"Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer","volume":"26","author":"F Di Nicolantonio","year":"2008","journal-title":"J Clin Oncol"},{"issue":"08","key":"ref45","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/S1470-2045(13)70163-3","article-title":"Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial","volume":"14","author":"M T Seymour","year":"2013","journal-title":"Lancet Oncol"},{"issue":"10","key":"ref46","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1016\/j.ejca.2012.02.057","article-title":"Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials","volume":"48","author":"C Bokemeyer","year":"2012","journal-title":"Eur J Cancer"},{"issue":"26","key":"ref47","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"D T Le","year":"2015","journal-title":"N Engl J Med"},{"issue":"10","key":"ref48","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.5858\/arpa.2011-0035-RA","article-title":"Microsatellite instability and colorectal cancer","volume":"135","author":"K B Geiersbach","year":"2011","journal-title":"Arch Pathol Lab Med"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"1178772","DOI":"10.3389\/fonc.2023.1178772","article-title":"Concordance between microsatellite instability and mismatch repair protein expression in colorectal cancer and their clinicopathological characteristics: a retrospective analysis of 502 cases","volume":"13","author":"M Ye","year":"2023","journal-title":"Front Oncol"},{"issue":"04","key":"ref50","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1158\/1078-0432.CCR-15-1678","article-title":"Microsatellite instability as a biomarker for PD-1 blockade","volume":"22","author":"J C Dudley","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"05","key":"ref51","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1093\/annonc\/mdu100","article-title":"Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H)","volume":"25","author":"J Goldstein","year":"2014","journal-title":"Ann Oncol"},{"issue":"23","key":"ref52","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in microsatellite-instability-high advanced colorectal cancer","volume":"383","author":"T Andr\u00e9","year":"2020","journal-title":"N Engl J Med"},{"issue":"99","key":"ref53","doi-asserted-by":"crossref","first-page":"99ra86","DOI":"10.1126\/scitranslmed.3002442","article-title":"Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab","volume":"3","author":"K Yonesaka","year":"2011","journal-title":"Sci Transl Med"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"3517","DOI":"10.1200\/JCO.2016.34.15_suppl.3517","article-title":"HER2 amplification as a negative predictive biomarker for anti-epidermal growth factor receptor antibody therapy in metastatic colorectal cancer","volume":"34","author":"K PS Raghav","year":"2016","journal-title":"J Clin Oncol"},{"issue":"06","key":"ref55","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S1470-2045(16)00150-9","article-title":"Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12\/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial","volume":"17","author":"A Sartore-Bianchi","year":"2016","journal-title":"Lancet Oncol"},{"issue":"04","key":"ref56","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/S1470-2045(18)30904-5","article-title":"Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study","volume":"20","author":"F Meric-Bernstam","year":"2019","journal-title":"Lancet Oncol"},{"issue":"05","key":"ref57","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/S1470-2045(23)00150-X","article-title":"Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study","volume":"24","author":"J H Strickler","year":"2023","journal-title":"Lancet Oncol"},{"issue":"22","key":"ref58","doi-asserted-by":"crossref","first-page":"5750","DOI":"10.3390\/cancers13225750","article-title":"Next-generation sequencing targeted panel in routine care for metastatic colon cancers","volume":"13","author":"A Bayle","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"08","key":"ref59","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children","volume":"378","author":"A Drilon","year":"2018","journal-title":"N Engl J Med"},{"issue":"06","key":"ref60","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1093\/annonc\/mdx125","article-title":"Plasma ctDNA RAS mutation analysis for the diagnosis and treatment monitoring of metastatic colorectal cancer patients","volume":"28","author":"J Vidal","year":"2017","journal-title":"Ann Oncol"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(07)61087-3","article-title":"Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial","volume":"370","author":"M T Seymour","year":"2007","journal-title":"Lancet"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0140-6736(07)61086-1","article-title":"Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial","volume":"370","author":"M Koopman","year":"2007","journal-title":"Lancet"},{"issue":"11","key":"ref63","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/S1470-2045(11)70199-1","article-title":"Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000-05): an open-label, randomised, phase 3 trial","volume":"12","author":"M Ducreux","year":"2011","journal-title":"Lancet Oncol"},{"issue":"02","key":"ref64","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1200\/JCO.2004.05.113","article-title":"FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study","volume":"22","author":"C Tournigand","year":"2004","journal-title":"J Clin Oncol"},{"issue":"22","key":"ref65","doi-asserted-by":"crossref","first-page":"4866","DOI":"10.1200\/JCO.2005.07.113","article-title":"Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale","volume":"23","author":"G Colucci","year":"2005","journal-title":"J Clin Oncol"},{"issue":"27","key":"ref66","doi-asserted-by":"crossref","first-page":"4224","DOI":"10.1200\/JCO.2006.09.8467","article-title":"Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial","volume":"25","author":"E D\u00edaz-Rubio","year":"2007","journal-title":"J Clin Oncol"},{"issue":"27","key":"ref67","doi-asserted-by":"crossref","first-page":"4217","DOI":"10.1200\/JCO.2006.09.2684","article-title":"Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group","volume":"25","author":"R Porschen","year":"2007","journal-title":"J Clin Oncol"},{"issue":"12","key":"ref68","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1200\/JCO.2007.14.9898","article-title":"Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil\/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer","volume":"26","author":"J Cassidy","year":"2008","journal-title":"J Clin Oncol"},{"issue":"02","key":"ref69","doi-asserted-by":"crossref","first-page":"94","DOI":"10.3109\/07357907.2015.1104689","article-title":"XELOX vs. FOLFOX in metastatic colorectal cancer: an updated meta-analysis","volume":"34","author":"Y Guo","year":"2016","journal-title":"Cancer Invest"},{"issue":"19","key":"ref70","doi-asserted-by":"crossref","first-page":"4006","DOI":"10.1200\/JCO.2002.12.075","article-title":"Biweekly chemotherapy with oxaliplatin, irinotecan, infusional fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer","volume":"20","author":"A Falcone","year":"2002","journal-title":"J Clin Oncol"},{"issue":"11","key":"ref71","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1200\/JCO.2002.08.015","article-title":"Triplet combination with irinotecan plus oxaliplatin plus continuous-infusion fluorouracil and leucovorin as first-line treatment in metastatic colorectal cancer: a multicenter phase II trial","volume":"20","author":"J Souglakos","year":"2002","journal-title":"J Clin Oncol"},{"issue":"07","key":"ref72","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1200\/JCO.2004.11.037","article-title":"Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment","volume":"22","author":"A Grothey","year":"2004","journal-title":"J Clin Oncol"},{"issue":"13","key":"ref73","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1200\/JCO.2006.09.0928","article-title":"Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest","volume":"25","author":"A Falcone","year":"2007","journal-title":"J Clin Oncol"},{"issue":"06","key":"ref74","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/sj.bjc.6603011","article-title":"FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG)","volume":"94","author":"J Souglakos","year":"2006","journal-title":"Br J Cancer"},{"key":"ref75","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.critrevonc.2017.08.006","article-title":"Triplet (FOLFOXIRI) versus doublet (FOLFOX or FOLFIRI) backbone chemotherapy as first-line treatment of metastatic colorectal cancer: a systematic review and meta-analysis","volume":"118","author":"R P Marques","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"issue":"13","key":"ref76","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/S1470-2045(15)00122-9","article-title":"FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study","volume":"16","author":"C Cremolini","year":"2015","journal-title":"Lancet Oncol"},{"issue":"06","key":"ref77","doi-asserted-by":"crossref","first-page":"687","DOI":"10.6004\/jnccn.2018.7277","article-title":"Geriatric assessment, not ASA physical status, is associated with 6-month postoperative survival in patients with cancer aged \u226575 years","volume":"17","author":"A Shahrokni","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"issue":"11","key":"ref78","doi-asserted-by":"crossref","first-page":"e214158","DOI":"10.1001\/jamaoncol.2021.4158","article-title":"Geriatric assessment-driven intervention (GAIN) on chemotherapy-related toxic effects in older adults with cancer: a randomized clinical trial","volume":"7","author":"D Li","year":"2021","journal-title":"JAMA Oncol"},{"issue":"08","key":"ref79","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1634\/theoncologist.2016-0462","article-title":"Geriatric assessment predicts survival and competing mortality in elderly patients with early colorectal cancer: can it help in adjuvant therapy decision-making?","volume":"22","author":"M Antonio","year":"2017","journal-title":"Oncologist"},{"key":"ref80","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1016\/S0140-6736(21)01789-X","article-title":"Evaluation of geriatric assessment and management on the toxic effects of cancer treatment (GAP70+): a cluster-randomised study","volume":"398","author":"S G Mohile","year":"2021","journal-title":"Lancet"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1016\/S0140-6736(11)60399-1","article-title":"Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial","volume":"377","author":"M T Seymour","year":"2011","journal-title":"Lancet"},{"issue":"33","key":"ref82","doi-asserted-by":"crossref","first-page":"3967","DOI":"10.1200\/JCO.23.02722","article-title":"Oxaliplatin added to fluoropyrimidine\/bevacizumab as initial therapy for unresectable metastatic colorectal cancer in older patients: a multicenter, randomized, open-label phase III trial (JCOG1018)","volume":"42","author":"A Takashima","year":"2024","journal-title":"J Clin Oncol"},{"issue":"10","key":"ref83","doi-asserted-by":"crossref","first-page":"779","DOI":"10.7326\/0003-4819-113-10-779","article-title":"Colorectal cancer: evidence for distinct genetic categories based on proximal or distal tumor location","volume":"113","author":"J A Bufill","year":"1990","journal-title":"Ann Intern Med"},{"issue":"02","key":"ref84","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1001\/jamaoncol.2016.4227","article-title":"Prognostic survival associated with left-sided vs right-sided colon cancer: a systematic review and meta-analysis","volume":"3","author":"F Petrelli","year":"2017","journal-title":"JAMA Oncol"},{"key":"ref85","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ejca.2016.10.007","article-title":"The relevance of primary tumour location in patients with metastatic colorectal cancer: a meta-analysis of first-line clinical trials","volume":"70","author":"J W Holch","year":"2017","journal-title":"Eur J Cancer"},{"issue":"07","key":"ref86","doi-asserted-by":"crossref","first-page":"e173695","DOI":"10.1001\/jamaoncol.2017.3695","article-title":"Association of prognostic value of primary tumor location in stage III colon cancer with RAS and BRAF mutational status","volume":"4","author":"J Taieb","year":"2018","journal-title":"JAMA Oncol"},{"issue":"49","key":"ref87","doi-asserted-by":"crossref","first-page":"86356","DOI":"10.18632\/oncotarget.21169","article-title":"Comparative molecular analyses of left-sided colon, right-sided colon, and rectal cancers","volume":"8","author":"M E Salem","year":"2017","journal-title":"Oncotarget"},{"issue":"02","key":"ref88","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1001\/jamaoncol.2016.3797","article-title":"Prognostic and predictive relevance of primary tumor location in patients with RAS wild-type metastatic colorectal cancer: retrospective analyses of the CRYSTAL and FIRE-3 trials","volume":"3","author":"S Tejpar","year":"2017","journal-title":"JAMA Oncol"},{"issue":"08","key":"ref89","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1093\/annonc\/mdx119","article-title":"Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer: results from two randomized first-line panitumumab studies","volume":"28","author":"N Boeckx","year":"2017","journal-title":"Ann Oncol"},{"issue":"02","key":"ref90","first-page":"e9","article-title":"Impact of primary tumor site on bevacizumab efficacy in metastatic colorectal cancer","volume":"15","author":"H L Wong","year":"2016","journal-title":"Clin Colorectal Cancer"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1200\/JCO.2018.36.4_suppl.726","article-title":"Efficacy outcomes with bevacizumab added to chemotherapy (bev+CT) compared with chemotherapy alone (CT) in left- and right-sided tumors in metastatic colorectal cancer (mCRC)","volume":"36","author":"F Loupakis","year":"2018","journal-title":"J Clin Oncol"},{"issue":"08","key":"ref92","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1093\/annonc\/mdx175","article-title":"Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials","volume":"28","author":"D Arnold","year":"2017","journal-title":"Ann Oncol"},{"issue":"15","key":"ref93","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1001\/jama.2023.4428","article-title":"Panitumumab vs bevacizumab added to standard first-line chemotherapy and overall survival among patients with RAS wild-type, left-sided metastatic colorectal cancer: a randomized clinical trial","volume":"329","author":"J Watanabe","year":"2023","journal-title":"JAMA"},{"key":"ref95","doi-asserted-by":"crossref","first-page":"TPS3627","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS3627","article-title":"BREAKWATER: an open-label, multicenter, randomized, phase 3 study, with a safety lead-in (SLI), of first-line (1L) encorafenib (E) + cetuximab (C)\u2009\u00b1\u2009chemotherapy (CT) vs standard-of-care (SOC) CT for BRAF V600E-mutant metastatic colorectal cancer (mCRC)","volume":"41","author":"S Kopetz","year":"2023","journal-title":"J Clin Oncol"},{"issue":"23","key":"ref96","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"H Hurwitz","year":"2004","journal-title":"N Engl J Med"},{"issue":"12","key":"ref97","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1200\/JCO.2007.14.9930","article-title":"Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study","volume":"26","author":"L B Saltz","year":"2008","journal-title":"J Clin Oncol"},{"issue":"11","key":"ref98","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/S1470-2045(13)70154-2","article-title":"Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial","volume":"14","author":"D Cunningham","year":"2013","journal-title":"Lancet Oncol"},{"issue":"19","key":"ref99","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.1200\/JCO.2009.27.7723","article-title":"Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study","volume":"28","author":"N C Tebbutt","year":"2010","journal-title":"J Clin Oncol"},{"issue":"09","key":"ref100","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1634\/theoncologist.2013-0107","article-title":"Efficacy and safety of bevacizumab in metastatic colorectal cancer: pooled analysis from seven randomized controlled trials","volume":"18","author":"H I Hurwitz","year":"2013","journal-title":"Oncologist"},{"issue":"06","key":"ref101","doi-asserted-by":"crossref","first-page":"e2200306","DOI":"10.1200\/PO.22.00306","article-title":"Pertuzumab plus trastuzumab in patients with colorectal cancer with ERBB2 amplification or ERBB2\/3 mutations: results from the TAPUR study","volume":"6","author":"R Gupta","year":"2022","journal-title":"JCO Precis Oncol"},{"issue":"06","key":"ref102","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1470-2045(21)00086-3","article-title":"Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial","volume":"22","author":"S Siena","year":"2021","journal-title":"Lancet Oncol"},{"issue":"03","key":"ref103","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1200\/JCO.2005.03.0106","article-title":"OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer \u2013 a GERCOR study","volume":"24","author":"C Tournigand","year":"2006","journal-title":"J Clin Oncol"},{"issue":"34","key":"ref104","doi-asserted-by":"crossref","first-page":"5727","DOI":"10.1200\/JCO.2009.23.4344","article-title":"Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study","volume":"27","author":"B Chibaudel","year":"2009","journal-title":"J Clin Oncol"},{"key":"ref105","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1016\/S0140-6736(14)62004-3","article-title":"Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group","volume":"385","author":"L HJ Simkens","year":"2015","journal-title":"Lancet"},{"issue":"13","key":"ref106","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1016\/S1470-2045(15)00042-X","article-title":"Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial","volume":"16","author":"S Hegewisch-Becker","year":"2015","journal-title":"Lancet Oncol"},{"issue":"07","key":"ref107","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1200\/JCO.2017.75.2931","article-title":"Bevacizumab maintenance versus no maintenance during chemotherapy-free intervals in metastatic colorectal cancer: a randomized phase III trial (PRODIGE 9)","volume":"36","author":"T Aparicio","year":"2018","journal-title":"J Clin Oncol"},{"key":"ref108","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1200\/JCO.2018.36.4_suppl.789","article-title":"Comparative analysis of different maintenance regimens after first-line induction in patients with metastatic colorectal cancer","volume":"36","author":"A Mohamed","year":"2018","journal-title":"J Clin Oncol"},{"issue":"02","key":"ref109","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1002\/ijc.32110","article-title":"Panitumumab-based maintenance after oxaliplatin discontinuation in metastatic colorectal cancer: a retrospective analysis of two randomised trials","volume":"145","author":"D P Modest","year":"2019","journal-title":"Int J Cancer"},{"issue":"01","key":"ref110","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1200\/JCO.21.01332","article-title":"Panitumumab plus fluorouracil and folinic acid versus fluorouracil and folinic acid alone as maintenance therapy in RAS wild-type metastatic colorectal cancer: the randomized PANAMA trial (AIO KRK 0212)","volume":"40","author":"D P Modest","year":"2022","journal-title":"J Clin Oncol"},{"issue":"05","key":"ref111","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S1470-2045(22)00197-8","article-title":"Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study","volume":"23","author":"L A Diaz Jr","year":"2022","journal-title":"Lancet Oncol"},{"key":"ref112","doi-asserted-by":"crossref","first-page":"LBA768","DOI":"10.1200\/JCO.2024.42.3_suppl.LBA768","article-title":"Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for microsatellite instability-high\/mismatch repair-deficient (MSI-H\/dMMR) metastatic colorectal cancer (mCRC): first results of the CheckMate 8HW study","volume":"42","author":"T Andre","year":"2024","journal-title":"J Clin Oncol"},{"issue":"02","key":"ref113","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1200\/JCO.22.01015","article-title":"Low-dose immunotherapy in head and neck cancer: a randomized study","volume":"41","author":"V M Patil","year":"2023","journal-title":"J Clin Oncol"},{"key":"ref114","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.radonc.2020.02.008","article-title":"Association of tumor genomic factors and efficacy for metastasis-directed stereotactic body radiotherapy for oligometastatic colorectal cancer","volume":"146","author":"K R Jethwa","year":"2020","journal-title":"Radiother Oncol"},{"issue":"02","key":"ref115","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1097\/PPO.0000000000000438","article-title":"Prognostic and predictive biomarkers in oligometastatic disease","volume":"26","author":"K J Barnum","year":"2020","journal-title":"Cancer J"},{"issue":"06","key":"ref116","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.3390\/cancers15061827","article-title":"Oligo-metastatic cancers: putative biomarkers, emerging challenges and new perspectives","volume":"15","author":"A Ottaiano","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"03","key":"ref117","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/00000658-199909000-00004","article-title":"Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases","volume":"230","author":"Y Fong","year":"1999","journal-title":"Ann Surg"},{"issue":"23","key":"ref118","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1056\/NEJMoa032709","article-title":"Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer","volume":"350","author":"T Andr\u00e9","year":"2004","journal-title":"N Engl J Med"},{"issue":"12","key":"ref119","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S1470-2045(13)70447-9","article-title":"Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial","volume":"14","author":"B Nordlinger","year":"2013","journal-title":"Lancet Oncol"},{"key":"ref120","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ejca.2020.08.009","article-title":"Oligometastatic colorectal cancer: prognosis, role of locoregional treatments and impact of first-line chemotherapy-a pooled analysis of TRIBE and TRIBE2 studies by Gruppo Oncologico del Nord Ovest","volume":"139","author":"R Moretto","year":"2020","journal-title":"Eur J Cancer"},{"issue":"07","key":"ref121","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S1470-2045(23)00219-X","article-title":"First-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases (CAIRO5): an open-label, multicentre, randomised, controlled, phase 3 study from the Dutch Colorectal Cancer Group","volume":"24","author":"M JG Bond","year":"2023","journal-title":"Lancet Oncol"},{"issue":"10","key":"ref122","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/S1470-2045(16)30269-8","article-title":"FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial","volume":"17","author":"S Stintzing","year":"2016","journal-title":"Lancet Oncol"},{"issue":"10","key":"ref123","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1200\/JCO.20.02447","article-title":"Primary tumor resection plus chemotherapy versus chemotherapy alone for colorectal cancer patients with asymptomatic, synchronous unresectable metastases (JCOG1007; iPACS): a randomized clinical trial","volume":"39","author":"Y Kanemitsu","year":"2021","journal-title":"J Clin Oncol"},{"issue":"04","key":"ref124","first-page":"1387","article-title":"Intra-arterial infusion of irinotecan-loaded drug-eluting beads (DEBIRI) versus intravenous therapy (FOLFIRI) for hepatic metastases from colorectal cancer: final results of a phase III study","volume":"32","author":"G Fiorentini","year":"2012","journal-title":"Anticancer Res"},{"issue":"10","key":"ref125","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1093\/annonc\/mds053","article-title":"Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC Intergroup phase II study (EORTC 40004)","volume":"23","author":"T Ruers","year":"2012","journal-title":"Ann Oncol"},{"issue":"01","key":"ref126","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1080\/02656736.2021.1923836","article-title":"Stereotactic body radiation therapy for colorectal liver metastases","volume":"39","author":"I Mohamad","year":"2022","journal-title":"Int J Hyperthermia"},{"issue":"02","key":"ref127","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/S1470-2045(20)30599-4","article-title":"Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial","volume":"22","author":"F Qu\u00e9net","year":"2021","journal-title":"Lancet Oncol"},{"key":"ref128","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/S0140-6736(98)03085-2","article-title":"Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer","volume":"352","author":"P Rougier","year":"1998","journal-title":"Lancet"},{"key":"ref129","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/S0140-6736(98)02309-5","article-title":"Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer","volume":"352","author":"D Cunningham","year":"1998","journal-title":"Lancet"},{"issue":"12","key":"ref130","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1016\/j.ejca.2011.04.024","article-title":"Single-agent irinotecan or 5-fluorouracil and leucovorin (FOLFIRI) as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis","volume":"47","author":"S J Clarke","year":"2011","journal-title":"Eur J Cancer"},{"issue":"05","key":"ref131","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/S1470-2045(18)30140-2","article-title":"Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial","volume":"19","author":"R H Xu","year":"2018","journal-title":"Lancet Oncol"},{"issue":"11","key":"ref132","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1200\/JCO.2003.11.126","article-title":"Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial","volume":"21","author":"M L Rothenberg","year":"2003","journal-title":"J Clin Oncol"},{"issue":"10","key":"ref133","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1093\/annonc\/mdn370","article-title":"Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil\/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study","volume":"19","author":"M L Rothenberg","year":"2008","journal-title":"Ann Oncol"},{"issue":"04","key":"ref134","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1093\/annonc\/mdv012","article-title":"Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial","volume":"26","author":"G Masi","year":"2015","journal-title":"Ann Oncol"},{"issue":"01","key":"ref135","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(12)70477-1","article-title":"Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial","volume":"14","author":"J Bennouna","year":"2013","journal-title":"Lancet Oncol"},{"issue":"01","key":"ref136","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s12032-014-0325-9","article-title":"A multi-center randomized phase II clinical study of bevacizumab plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) compared with FOLFIRI alone as second-line treatment for Chinese patients with metastatic colorectal cancer","volume":"32","author":"R Cao","year":"2015","journal-title":"Med Oncol"},{"issue":"12","key":"ref137","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1200\/JCO.2006.09.6305","article-title":"Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200","volume":"25","author":"B J Giantonio","year":"2007","journal-title":"J Clin Oncol"},{"issue":"07","key":"ref138","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1093\/annonc\/mdv197","article-title":"FOLFIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer after first-line bevacizumab plus oxaliplatin-based therapy: the randomized phase III EAGLE study","volume":"26","author":"S Iwamoto","year":"2015","journal-title":"Ann Oncol"},{"issue":"05","key":"ref139","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S1470-2045(15)70127-0","article-title":"Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study","volume":"16","author":"J Tabernero","year":"2015","journal-title":"Lancet Oncol"},{"issue":"12","key":"ref140","doi-asserted-by":"crossref","first-page":"2932","DOI":"10.1093\/annonc\/mdx514","article-title":"Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab","volume":"28","author":"D Arnold","year":"2017","journal-title":"Ann Oncol"},{"issue":"31","key":"ref141","doi-asserted-by":"crossref","first-page":"4706","DOI":"10.1200\/JCO.2009.27.6055","article-title":"Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer","volume":"28","author":"M Peeters","year":"2010","journal-title":"J Clin Oncol"},{"issue":"01","key":"ref142","doi-asserted-by":"crossref","first-page":"10426","DOI":"10.1038\/s41598-017-11048-9","article-title":"Impact of second-line cetuximab-containing therapy in patients with KRAS wild-type metastatic colorectal cancer: results from the ITACa randomized clinical trial","volume":"7","author":"A Passardi","year":"2017","journal-title":"Sci Rep"},{"issue":"04","key":"ref143","doi-asserted-by":"crossref","first-page":"e000353","DOI":"10.1136\/esmoopen-2018-000353","article-title":"Optimising the use of cetuximab in the continuum of care for patients with metastatic colorectal cancer","volume":"3","author":"R M Goldberg","year":"2018","journal-title":"ESMO Open"},{"issue":"06","key":"ref144","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1093\/annonc\/mdw136","article-title":"Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): a randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX","volume":"27","author":"F Ciardiello","year":"2016","journal-title":"Ann Oncol"},{"issue":"10","key":"ref145","doi-asserted-by":"crossref","first-page":"11380","DOI":"10.18632\/oncotarget.7193","article-title":"Efficacy of continued cetuximab for unresectable metastatic colorectal cancer after disease progression during first-line cetuximab-based chemotherapy: a retrospective cohort study","volume":"7","author":"Q Feng","year":"2016","journal-title":"Oncotarget"},{"issue":"04","key":"ref146","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1159\/000346328","article-title":"A phase II study of high-dose cetuximab plus irinotecan in colorectal cancer patients with KRAS wild-type tumors who progressed after standard dose of cetuximab plus irinotecan","volume":"84","author":"A A Fora","year":"2013","journal-title":"Oncology"},{"issue":"01","key":"ref147","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1186\/s12885-015-1701-3","article-title":"Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response","volume":"15","author":"X Liu","year":"2015","journal-title":"BMC Cancer"},{"issue":"09","key":"ref148","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1093\/annonc\/mdr623","article-title":"Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?","volume":"23","author":"D Santini","year":"2012","journal-title":"Ann Oncol"},{"key":"ref149","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","article-title":"Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"A Grothey","year":"2013","journal-title":"Lancet"},{"issue":"06","key":"ref150","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S1470-2045(15)70156-7","article-title":"Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"16","author":"J Li","year":"2015","journal-title":"Lancet Oncol"},{"issue":"08","key":"ref151","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/S1470-2045(19)30272-4","article-title":"Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study","volume":"20","author":"T S Bekaii-Saab","year":"2019","journal-title":"Lancet Oncol"},{"key":"ref152","doi-asserted-by":"crossref","first-page":"viii156","DOI":"10.1093\/annonc\/mdy281.015","article-title":"Prospective evaluation of regorafenib dose escalation strategy with low starting dose in patients with colorectal cancer","volume":"29","author":"T Masuishi","year":"2018","journal-title":"Ann Oncol"},{"key":"ref153","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1200\/JCO.2020.38.4_suppl.116","article-title":"Regorafenib dose escalation therapy for patients with refractory metastatic colorectal cancer (RECC Study)","volume":"38","author":"M Nakamura","year":"2020","journal-title":"J Clin Oncol"},{"issue":"20","key":"ref154","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","article-title":"Randomized trial of TAS-102 for refractory metastatic colorectal cancer","volume":"372","author":"R J Mayer","year":"2015","journal-title":"N Engl J Med"},{"issue":"03","key":"ref155","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/S1470-2045(19)30827-7","article-title":"TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial","volume":"21","author":"P Pfeiffer","year":"2020","journal-title":"Lancet Oncol"},{"issue":"03","key":"ref156","doi-asserted-by":"crossref","first-page":"e469","DOI":"10.1634\/theoncologist.2019-0541","article-title":"Bevacizumab in combination with TAS-102 improves clinical outcomes in patients with refractory metastatic colorectal cancer: a retrospective study","volume":"25","author":"H Fujii","year":"2020","journal-title":"Oncologist"},{"issue":"13","key":"ref157","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1200\/JCO.2006.08.1620","article-title":"Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer","volume":"25","author":"E Van Cutsem","year":"2007","journal-title":"J Clin Oncol"},{"issue":"10","key":"ref158","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1038\/bjc.2016.309","article-title":"A phase 3 trial evaluating panitumumab plus best supportive care vs best supportive care in chemorefractory wild-type KRAS or RAS metastatic colorectal cancer","volume":"115","author":"T W Kim","year":"2016","journal-title":"Br J Cancer"},{"issue":"06","key":"ref159","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S1470-2045(14)70118-4","article-title":"Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study","volume":"15","author":"T J Price","year":"2014","journal-title":"Lancet Oncol"},{"key":"ref160","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.2147\/DDDT.S85567","article-title":"Phase II study of reintroduction of oxaliplatin for advanced colorectal cancer in patients previously treated with oxaliplatin and irinotecan: RE-OPEN study","volume":"9","author":"M Suenaga","year":"2015","journal-title":"Drug Des Devel Ther"},{"issue":"08","key":"ref161","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1093\/annonc\/mdh305","article-title":"Oxaliplatin reintroduction in patients previously treated with leucovorin, fluorouracil and oxaliplatin for metastatic colorectal cancer","volume":"15","author":"F Maindrault-Goebel","year":"2004","journal-title":"Ann Oncol"},{"issue":"04","key":"ref162","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1200\/JCO.20.02088","article-title":"Encorafenib plus cetuximab as a new standard of care for previously treated BRAF V600E-mutant metastatic colorectal cancer: updated survival results and subgroup analyses from the BEACON study","volume":"39","author":"J Tabernero","year":"2021","journal-title":"J Clin Oncol"},{"key":"ref163","doi-asserted-by":"crossref","first-page":"1268783","DOI":"10.3389\/fonc.2023.1268783","article-title":"The value of carcinoembryonic antigen stage in staging, prognosis, and management of colorectal cancer: results from two cohort studies","volume":"13","author":"H Xie","year":"2023","journal-title":"Front Oncol"},{"issue":"06","key":"ref164","doi-asserted-by":"crossref","first-page":"294","DOI":"10.3393\/ac.2019.11.13","article-title":"A review of the role of carcinoembryonic antigen in clinical practice","volume":"35","author":"C Hall","year":"2019","journal-title":"Ann Coloproctol"},{"issue":"02","key":"ref166","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/cpt.911","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update","volume":"103","author":"U Amstutz","year":"2018","journal-title":"Clin Pharmacol Ther"},{"issue":"04","key":"ref167","doi-asserted-by":"crossref","first-page":"182","DOI":"10.4103\/2278-330X.195338","article-title":"Dihydropyrimidine dehydrogenase mutation in neoadjuvant chemotherapy in head and neck cancers: Myth or reality?","volume":"5","author":"V M Patil","year":"2016","journal-title":"South Asian J Cancer"},{"issue":"03","key":"ref168","doi-asserted-by":"crossref","first-page":"380","DOI":"10.21037\/jgo.2016.03.02","article-title":"Dihydro pyrimidine dehydrogenase deficiency in patients treated with capecitabine based regimens: a tertiary care centre experience","volume":"7","author":"A Sahu","year":"2016","journal-title":"J Gastrointest Oncol"},{"issue":"11","key":"ref169","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","article-title":"A guide to cancer immunotherapy: from T cell basic science to clinical practice","volume":"20","author":"A D Waldman","year":"2020","journal-title":"Nat Rev Immunol"},{"issue":"04","key":"ref170","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.3390\/biomedicines11041032","article-title":"Low-dose immunotherapy: Is it just an illusion?","volume":"11","author":"F Meriggi","year":"2023","journal-title":"Biomedicines"}],"container-title":["South Asian Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0045-1809380.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T11:13:09Z","timestamp":1781176389000},"score":1,"resource":{"primary":{"URL":"https:\/\/journal.sajc.org\/consensus-statements-for-clinical-practice-in-advanced-metastatic-colorectal-cancers-in-india-using-a-modified-delphi-method\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":168,"journal-issue":{"issue":"02","published-online":{"date-parts":[[2025,12,18]]},"published-print":{"date-parts":[[2025,4]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0045-1809380","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["2278-330X","2278-4306"],"issn-type":[{"value":"2278-330X","type":"print"},{"value":"2278-4306","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4]]}}}